Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
inotuzumab ozogamicin
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Inotuzumab ozogamicin is an antibody-drug conjugate (ADC) used to treat B-cell precursor acute lymphoblastic leukemia (ALL), particularly in cases that are relapsed or refractory. It consists of a humanized monoclonal IgG4 antibody targeting the CD22 antigen on B cells, covalently linked to the cytotoxic agent N-acetyl-gamma-calicheamicin via an acid-cleavable linker. Upon binding to CD22-expressing tumor cells, the drug-antibody complex is internalized and trafficked into lysosomes where the linker is hydrolyzed, releasing calicheamicin inside the cell. Calicheamicin binds DNA and induces double-strand breaks, leading to cell cycle arrest and apoptosis. Inotuzumab ozogamicin was developed by Wyeth (now part of Pfizer) and is marketed under the brand name Besponsa[3][5][6][7][8].
- Brand names
- Besponsa
- Other names
- inotuzumab ozogamicinCMC-544CMC544CMC 544
02
Targets
CD22 (Cluster of Differentiation 22)DNA
Beyond the preview
Go deeper on inotuzumab ozogamicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inotuzumab ozogamicin.